nodes	percent_of_prediction	percent_of_DWPC	metapath
Isoniazid—CYP1A2—Carmustine—lymphatic system cancer	0.178	0.234	CbGbCtD
Isoniazid—CYP2E1—Mitoxantrone—lymphatic system cancer	0.145	0.19	CbGbCtD
Isoniazid—CYP2C19—Teniposide—lymphatic system cancer	0.13	0.171	CbGbCtD
Isoniazid—CYP2C9—Teniposide—lymphatic system cancer	0.108	0.142	CbGbCtD
Isoniazid—CYP3A4—Cytarabine—lymphatic system cancer	0.0638	0.0837	CbGbCtD
Isoniazid—CYP3A4—Teniposide—lymphatic system cancer	0.0628	0.0824	CbGbCtD
Isoniazid—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0439	0.0577	CbGbCtD
Isoniazid—CYP3A4—Vincristine—lymphatic system cancer	0.0302	0.0397	CbGbCtD
Isoniazid—Neurotoxicity—Teniposide—lymphatic system cancer	0.0134	0.0563	CcSEcCtD
Isoniazid—Metabolic acidosis—Teniposide—lymphatic system cancer	0.0131	0.0552	CcSEcCtD
Isoniazid—Neurotoxicity—Fludarabine—lymphatic system cancer	0.0118	0.0495	CcSEcCtD
Isoniazid—Metabolic acidosis—Fludarabine—lymphatic system cancer	0.0115	0.0485	CcSEcCtD
Isoniazid—Optic neuritis—Fludarabine—lymphatic system cancer	0.00741	0.0312	CcSEcCtD
Isoniazid—Neurotoxicity—Vincristine—lymphatic system cancer	0.00718	0.0302	CcSEcCtD
Isoniazid—Hepatic function abnormal—Teniposide—lymphatic system cancer	0.00431	0.0181	CcSEcCtD
Isoniazid—Reaction gastrointestinal—Methotrexate—lymphatic system cancer	0.00405	0.017	CcSEcCtD
Isoniazid—Diabetic—Methotrexate—lymphatic system cancer	0.00405	0.017	CcSEcCtD
Isoniazid—Jaundice—Mechlorethamine—lymphatic system cancer	0.00384	0.0161	CcSEcCtD
Isoniazid—Neuritis—Vincristine—lymphatic system cancer	0.00373	0.0157	CcSEcCtD
Isoniazid—Agranulocytosis—Mechlorethamine—lymphatic system cancer	0.00367	0.0154	CcSEcCtD
Isoniazid—Neurotoxicity—Methotrexate—lymphatic system cancer	0.00349	0.0147	CcSEcCtD
Isoniazid—Neuropathy peripheral—Teniposide—lymphatic system cancer	0.00284	0.012	CcSEcCtD
Isoniazid—Gynaecomastia—Carmustine—lymphatic system cancer	0.00261	0.011	CcSEcCtD
Isoniazid—Hyperglycaemia—Fludarabine—lymphatic system cancer	0.00258	0.0109	CcSEcCtD
Isoniazid—Neuropathy peripheral—Fludarabine—lymphatic system cancer	0.0025	0.0105	CcSEcCtD
Isoniazid—Thrombocytopenia—Mechlorethamine—lymphatic system cancer	0.00246	0.0103	CcSEcCtD
Isoniazid—Diabetes mellitus—Carmustine—lymphatic system cancer	0.00244	0.0102	CcSEcCtD
Isoniazid—Anorexia—Mechlorethamine—lymphatic system cancer	0.00239	0.0101	CcSEcCtD
Isoniazid—Eruption—Methotrexate—lymphatic system cancer	0.0022	0.00924	CcSEcCtD
Isoniazid—Decreased appetite—Mechlorethamine—lymphatic system cancer	0.00218	0.00918	CcSEcCtD
Isoniazid—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00185	0.00778	CcSEcCtD
Isoniazid—Ill-defined disorder—Fludarabine—lymphatic system cancer	0.00185	0.00778	CcSEcCtD
Isoniazid—Thrombocytopenia—Teniposide—lymphatic system cancer	0.00181	0.00762	CcSEcCtD
Isoniazid—Malaise—Fludarabine—lymphatic system cancer	0.0018	0.00756	CcSEcCtD
Isoniazid—Anorexia—Teniposide—lymphatic system cancer	0.00176	0.00742	CcSEcCtD
Isoniazid—Convulsion—Fludarabine—lymphatic system cancer	0.00173	0.00726	CcSEcCtD
Isoniazid—Discomfort—Fludarabine—lymphatic system cancer	0.00168	0.00705	CcSEcCtD
Isoniazid—Hyperglycaemia—Carmustine—lymphatic system cancer	0.00165	0.00695	CcSEcCtD
Isoniazid—Decreased appetite—Teniposide—lymphatic system cancer	0.00161	0.00677	CcSEcCtD
Isoniazid—Neuropathy peripheral—Carmustine—lymphatic system cancer	0.0016	0.00673	CcSEcCtD
Isoniazid—Vomiting—Mechlorethamine—lymphatic system cancer	0.0016	0.00671	CcSEcCtD
Isoniazid—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.00159	0.0067	CcSEcCtD
Isoniazid—Rash—Mechlorethamine—lymphatic system cancer	0.00158	0.00666	CcSEcCtD
Isoniazid—Anorexia—Fludarabine—lymphatic system cancer	0.00155	0.00652	CcSEcCtD
Isoniazid—Hyperglycaemia—Mitoxantrone—lymphatic system cancer	0.00154	0.00646	CcSEcCtD
Isoniazid—Neuropathy peripheral—Vincristine—lymphatic system cancer	0.00153	0.00642	CcSEcCtD
Isoniazid—Feeling abnormal—Teniposide—lymphatic system cancer	0.00153	0.00641	CcSEcCtD
Isoniazid—Nausea—Mechlorethamine—lymphatic system cancer	0.00149	0.00627	CcSEcCtD
Isoniazid—Hyperbilirubinaemia—Methotrexate—lymphatic system cancer	0.00149	0.00625	CcSEcCtD
Isoniazid—Jaundice—Mitoxantrone—lymphatic system cancer	0.00148	0.00622	CcSEcCtD
Isoniazid—Body temperature increased—Teniposide—lymphatic system cancer	0.00146	0.00615	CcSEcCtD
Isoniazid—Paraesthesia—Fludarabine—lymphatic system cancer	0.00146	0.00614	CcSEcCtD
Isoniazid—Dyspepsia—Fludarabine—lymphatic system cancer	0.00143	0.00602	CcSEcCtD
Isoniazid—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.00142	0.00596	CcSEcCtD
Isoniazid—Decreased appetite—Fludarabine—lymphatic system cancer	0.00141	0.00595	CcSEcCtD
Isoniazid—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.0014	0.00591	CcSEcCtD
Isoniazid—Fatigue—Fludarabine—lymphatic system cancer	0.0014	0.0059	CcSEcCtD
Isoniazid—Vasculitis—Methotrexate—lymphatic system cancer	0.00138	0.00582	CcSEcCtD
Isoniazid—Hypersensitivity—Teniposide—lymphatic system cancer	0.00136	0.00574	CcSEcCtD
Isoniazid—Hepatitis—Mitoxantrone—lymphatic system cancer	0.00136	0.00573	CcSEcCtD
Isoniazid—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00136	0.0057	CcSEcCtD
Isoniazid—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00134	0.00564	CcSEcCtD
Isoniazid—Asthenia—Teniposide—lymphatic system cancer	0.00133	0.00559	CcSEcCtD
Isoniazid—Malaise—Bleomycin—lymphatic system cancer	0.00132	0.00554	CcSEcCtD
Isoniazid—Body temperature increased—Fludarabine—lymphatic system cancer	0.00129	0.00541	CcSEcCtD
Isoniazid—Aplastic anaemia—Methotrexate—lymphatic system cancer	0.00127	0.00534	CcSEcCtD
Isoniazid—Discomfort—Bleomycin—lymphatic system cancer	0.00123	0.00517	CcSEcCtD
Isoniazid—Gynaecomastia—Methotrexate—lymphatic system cancer	0.00121	0.00509	CcSEcCtD
Isoniazid—Hypersensitivity—Fludarabine—lymphatic system cancer	0.0012	0.00504	CcSEcCtD
Isoniazid—Vomiting—Teniposide—lymphatic system cancer	0.00118	0.00495	CcSEcCtD
Isoniazid—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00117	0.00491	CcSEcCtD
Isoniazid—Asthenia—Fludarabine—lymphatic system cancer	0.00117	0.00491	CcSEcCtD
Isoniazid—Rash—Teniposide—lymphatic system cancer	0.00117	0.00491	CcSEcCtD
Isoniazid—Lymphadenopathy—Methotrexate—lymphatic system cancer	0.00115	0.00484	CcSEcCtD
Isoniazid—Anorexia—Bleomycin—lymphatic system cancer	0.00114	0.00478	CcSEcCtD
Isoniazid—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.00113	0.00474	CcSEcCtD
Isoniazid—Convulsion—Carmustine—lymphatic system cancer	0.00111	0.00465	CcSEcCtD
Isoniazid—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.0011	0.00463	CcSEcCtD
Isoniazid—Nausea—Teniposide—lymphatic system cancer	0.0011	0.00462	CcSEcCtD
Isoniazid—Paraesthesia—Bleomycin—lymphatic system cancer	0.00107	0.0045	CcSEcCtD
Isoniazid—Malaise—Mitoxantrone—lymphatic system cancer	0.00107	0.0045	CcSEcCtD
Isoniazid—Convulsion—Vincristine—lymphatic system cancer	0.00106	0.00444	CcSEcCtD
Isoniazid—Decreased appetite—Bleomycin—lymphatic system cancer	0.00104	0.00436	CcSEcCtD
Isoniazid—Vomiting—Fludarabine—lymphatic system cancer	0.00103	0.00435	CcSEcCtD
Isoniazid—Convulsion—Mitoxantrone—lymphatic system cancer	0.00103	0.00432	CcSEcCtD
Isoniazid—Rash—Fludarabine—lymphatic system cancer	0.00103	0.00431	CcSEcCtD
Isoniazid—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00102	0.00429	CcSEcCtD
Isoniazid—Discomfort—Mitoxantrone—lymphatic system cancer	0.000997	0.0042	CcSEcCtD
Isoniazid—Anorexia—Carmustine—lymphatic system cancer	0.000992	0.00417	CcSEcCtD
Isoniazid—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000983	0.00413	CcSEcCtD
Isoniazid—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000973	0.00409	CcSEcCtD
Isoniazid—Nausea—Fludarabine—lymphatic system cancer	0.000966	0.00406	CcSEcCtD
Isoniazid—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000948	0.00399	CcSEcCtD
Isoniazid—Anorexia—Vincristine—lymphatic system cancer	0.000947	0.00398	CcSEcCtD
Isoniazid—Body temperature increased—Bleomycin—lymphatic system cancer	0.000943	0.00397	CcSEcCtD
Isoniazid—Paraesthesia—Carmustine—lymphatic system cancer	0.000935	0.00393	CcSEcCtD
Isoniazid—Anorexia—Mitoxantrone—lymphatic system cancer	0.000923	0.00388	CcSEcCtD
Isoniazid—Decreased appetite—Carmustine—lymphatic system cancer	0.000905	0.00381	CcSEcCtD
Isoniazid—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000899	0.00378	CcSEcCtD
Isoniazid—Paraesthesia—Vincristine—lymphatic system cancer	0.000892	0.00375	CcSEcCtD
Isoniazid—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000879	0.0037	CcSEcCtD
Isoniazid—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000869	0.00366	CcSEcCtD
Isoniazid—Decreased appetite—Vincristine—lymphatic system cancer	0.000864	0.00363	CcSEcCtD
Isoniazid—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000858	0.00361	CcSEcCtD
Isoniazid—Feeling abnormal—Carmustine—lymphatic system cancer	0.000858	0.00361	CcSEcCtD
Isoniazid—Fatigue—Vincristine—lymphatic system cancer	0.000857	0.0036	CcSEcCtD
Isoniazid—Asthenia—Bleomycin—lymphatic system cancer	0.000856	0.0036	CcSEcCtD
Isoniazid—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000852	0.00358	CcSEcCtD
Isoniazid—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000841	0.00354	CcSEcCtD
Isoniazid—Eosinophilia—Methotrexate—lymphatic system cancer	0.00084	0.00353	CcSEcCtD
Isoniazid—Fatigue—Mitoxantrone—lymphatic system cancer	0.000834	0.00351	CcSEcCtD
Isoniazid—Body temperature increased—Carmustine—lymphatic system cancer	0.000823	0.00346	CcSEcCtD
Isoniazid—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000798	0.00335	CcSEcCtD
Isoniazid—Body temperature increased—Vincristine—lymphatic system cancer	0.000786	0.0033	CcSEcCtD
Isoniazid—Hypersensitivity—Carmustine—lymphatic system cancer	0.000767	0.00323	CcSEcCtD
Isoniazid—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000765	0.00322	CcSEcCtD
Isoniazid—Vomiting—Bleomycin—lymphatic system cancer	0.000758	0.00319	CcSEcCtD
Isoniazid—Rash—Bleomycin—lymphatic system cancer	0.000752	0.00316	CcSEcCtD
Isoniazid—Asthenia—Carmustine—lymphatic system cancer	0.000747	0.00314	CcSEcCtD
Isoniazid—Hypersensitivity—Vincristine—lymphatic system cancer	0.000732	0.00308	CcSEcCtD
Isoniazid—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000713	0.003	CcSEcCtD
Isoniazid—Asthenia—Vincristine—lymphatic system cancer	0.000713	0.003	CcSEcCtD
Isoniazid—Nausea—Bleomycin—lymphatic system cancer	0.000708	0.00298	CcSEcCtD
Isoniazid—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000706	0.00297	CcSEcCtD
Isoniazid—Asthenia—Mitoxantrone—lymphatic system cancer	0.000694	0.00292	CcSEcCtD
Isoniazid—Hepatitis—Methotrexate—lymphatic system cancer	0.000679	0.00285	CcSEcCtD
Isoniazid—Vomiting—Carmustine—lymphatic system cancer	0.000662	0.00278	CcSEcCtD
Isoniazid—Rash—Carmustine—lymphatic system cancer	0.000656	0.00276	CcSEcCtD
Isoniazid—Vomiting—Vincristine—lymphatic system cancer	0.000632	0.00266	CcSEcCtD
Isoniazid—Rash—Vincristine—lymphatic system cancer	0.000627	0.00264	CcSEcCtD
Isoniazid—Nausea—Carmustine—lymphatic system cancer	0.000618	0.0026	CcSEcCtD
Isoniazid—Vomiting—Mitoxantrone—lymphatic system cancer	0.000615	0.00259	CcSEcCtD
Isoniazid—Rash—Mitoxantrone—lymphatic system cancer	0.00061	0.00257	CcSEcCtD
Isoniazid—Nausea—Vincristine—lymphatic system cancer	0.00059	0.00248	CcSEcCtD
Isoniazid—Nausea—Mitoxantrone—lymphatic system cancer	0.000575	0.00242	CcSEcCtD
Isoniazid—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000548	0.00231	CcSEcCtD
Isoniazid—Malaise—Methotrexate—lymphatic system cancer	0.000533	0.00224	CcSEcCtD
Isoniazid—Convulsion—Methotrexate—lymphatic system cancer	0.000512	0.00215	CcSEcCtD
Isoniazid—Discomfort—Methotrexate—lymphatic system cancer	0.000497	0.00209	CcSEcCtD
Isoniazid—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000472	0.00199	CcSEcCtD
Isoniazid—Anorexia—Methotrexate—lymphatic system cancer	0.00046	0.00193	CcSEcCtD
Isoniazid—Paraesthesia—Methotrexate—lymphatic system cancer	0.000433	0.00182	CcSEcCtD
Isoniazid—Dyspepsia—Methotrexate—lymphatic system cancer	0.000424	0.00179	CcSEcCtD
Isoniazid—Decreased appetite—Methotrexate—lymphatic system cancer	0.000419	0.00176	CcSEcCtD
Isoniazid—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000416	0.00175	CcSEcCtD
Isoniazid—Fatigue—Methotrexate—lymphatic system cancer	0.000416	0.00175	CcSEcCtD
Isoniazid—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000397	0.00167	CcSEcCtD
Isoniazid—Body temperature increased—Methotrexate—lymphatic system cancer	0.000381	0.0016	CcSEcCtD
Isoniazid—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000355	0.00149	CcSEcCtD
Isoniazid—Asthenia—Methotrexate—lymphatic system cancer	0.000346	0.00146	CcSEcCtD
Isoniazid—Vomiting—Methotrexate—lymphatic system cancer	0.000307	0.00129	CcSEcCtD
Isoniazid—Rash—Methotrexate—lymphatic system cancer	0.000304	0.00128	CcSEcCtD
Isoniazid—Nausea—Methotrexate—lymphatic system cancer	0.000286	0.0012	CcSEcCtD
